Translational Genomics Research Institute;Van Andel Research Institute
发明人:
Jeffrey Paul MacKeigan,Katie R. Martin,Megan Lynn Goodall,Stephen Gately,Tong Wang
申请号：
US15102431
公开号：
US20170000784A1
申请日:
2014.12.05
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to compounds of Formula III, Formula 111(a), Formula V, Formula V(a), Formula A, Formula A 1, Formula A2, Formula A 3, or a pharmaceutically acceptable salt thereof that are useful as pharmaceutical agents, individually and/or in a combination with a chemotherapeutic agent: PLX-4032 (vemurafenib), or the catalytic mTOR inhibitor AZD8055, to treat a cancer and/or a cancer metastasis, for example a cancer harboring a BRAF protein kinase mutation and/or a HRAS protein mutation. Also, a method of treating and/or preventing malaria in a subject, the method comprising administering a therapeutically effective amount of a compound of Formula A, Formula A 1, Formula A2, Formula A 3, or a pharmaceutically acceptable salt thereof to the subject in need.
